Drilldown: Medicines
Appearance
Medicines > fda max:
20 mg/d
& onset
:
HbA1c effect at 12-16 weeks (slower than other classes)
or
~30 min 
& onset
:
HbA1c effect at 12-16 weeks (slower than other classes)
or
~30 min 
Use the filters below to narrow your results.
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) ·
Selective inhibitor of PDE5. Slightly higher PDE5/PDE6 selectivity vs sildenafil (less visual side effect) but more PDE1 cross-activity (occasional QT effects at high doses). (1)
Error: operator for the virtual field 'Medicines.classes' must be 'HOLDS', 'HOLDS NOT', 'HOLDS LIKE' or 'HOLDS NOT LIKE'.
There are no results for this report.

